Aeon Biopharma (AEON, Financial) has officially named Rob Bancroft as its new president and CEO, with his tenure beginning on April 29. Bancroft is also set to take a seat on the company's board of directors. With a robust background that includes over 25 years in the life sciences sector, Bancroft's experience covers a wide range of areas including biopharmaceuticals, medical devices, and healthcare technology.
Before this new role, Bancroft was the General Manager of the therapeutics division at Revance Therapeutics (RVNC). His diverse expertise is expected to bring valuable insights to Aeon Biopharma as the company continues to advance in its field.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for AEON Biopharma Inc (AEON, Financial) is $360.00 with a high estimate of $360.00 and a low estimate of $360.00. The average target implies an upside of 89,900.00% from the current price of $0.40. More detailed estimate data can be found on the AEON Biopharma Inc (AEON) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, AEON Biopharma Inc's (AEON, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
- CEO Buys, CFO Buys: Stocks that are bought by their CEO/CFOs.
- Insider Cluster Buys: Stocks that multiple company officers and directors have bought.
- Double Buys: Companies that both Gurus and Insiders are buying
- Triple Buys: Companies that both Gurus and Insiders are buying, and Company is buying back.
